Cough Science News
Find all editions of Cough Science News below and get access to the latest cough science developments, publications, and interviews with cough experts.
Find all editions of Cough Science News below and get access to the latest cough science developments, publications, and interviews with cough experts.
This month’s roundup explores placebo effects in RCC trials, the role of interoception in chronic cough, and the cost burden of persistent symptoms, plus insights from Dr. Nadia Giannetti.
New key cough science publications, Actigraph x Hyfe partnership and more
This year marked significant progress in cough monitoring, solidifying cough as a valuable biomarker in diverse therapeutic areas
New findings on refractory chronic cough (RCC), pulmonary tuberculosis, and pulmonary fibrosis. Plus latest white papers by Hyfe.
Cough Science News Oct 1 - new studies on cough-related stress urinary incontinence, COVID-19 detection in vaccinated adults, and the effectiveness of anti-reflux surgery for chronic cough. Plus, expert discussions from Hyfe's Cough Science Forum and the latest on FDA regulations for cough monitoring technologies
Cough Science News Oct 1 - new studies on cough-related stress urinary incontinence, COVID-19 detection in vaccinated adults, and the effectiveness of anti-reflux surgery for chronic cough. Plus, expert discussions from Hyfe's Cough Science Forum and the latest on FDA regulations for cough monitoring technologies
Cough Science News, August 2024 - Explore studies on cough variability, acute cough duration, and the cost burden of chronic cough. Plus, discover the world’s most comprehensive collection of cinematic coughs and upcoming events in cough science
CougH Science News July 2024 - latest in cough science. Insights on cough detection algorithms, pulmonary fibrosis, asthma diagnosis from cough sounds, and more. Plus, watch expert discussions and stay updated on upcoming events
Hyfe Cough Science News, June 2024. Latest research on cough in fibrotic ILD, high-dose inhaled corticosteroids for chronic cough, and family physicians’ approaches to managing chronic cough. Plus, insights from leading researchers and upcoming events
Cough Science News May 2024 - studies on cough monitoring for COVID-19 surveillance, the effectiveness of codeine for chronic cough, factors in refractory cough in IPF, and more. Plus, insights from researchers and upcoming events
Hyfe Cough Science News, March 2024 - insights on chronic cough management in the UK, common triggers in cough hypersensitivity, and a review of treatments for refractory cough. Plus, expert Q&A and upcoming cough science events.
Here’s What’s Inside
Key Takeaway: Cough frequency was reduced by up to 35%, with no adverse events, in this exploratory, single-blinded, nasal-saline-controlled study of inhaled alkaline HDS. 12 RCC patients, with cough rates of between 4 and 35 per hour, were monitored continuously for 1 week of baseline, 1 week of control, and 1 week of treatment.
Why It Matters: The study demonstrates the potential of inhaled alkaline HDS for RCC patients across the entire range of cough rates, by targeting upstream of cough receptor provocation. The study also demonstrates the potential of continuous cough monitoring to transform our understanding of treatment effects.
Key Takeaway: By monitoring pulmonary tuberculosis patients for 6 months of treatment, researchers demonstrated hourly cough rates dropped from 11 coughs-per-hour at week 1, to 1 cough-per-hour at the end of treatment in week 26.
Why It Matters: This study was the first of its kind monitoring tuberculosis patients’ cough for 6 consecutive months. It showed that community-based continuous cough-monitoring using digital technology is feasible in low resource settings but requires evolution of technology to overcome adherence issues and technical limitations.
Key Takeaways: This cohort study included 28 pulmonary fibrosis patients (excluding IPF) who experienced coughing, with median cough counts of 13.1 and 9.7 coughs per hour, measured in 24-hour snapshots. The study found that patient-reported outcomes did not always align with objective cough measurements, suggesting that a multidimensional approach is essential for assessing cough in pulmonary fibrosis trials and daily care.
Why it matters: This study demonstrates both intra- and inter-subject variability in 24-hour, daytime, and nighttime cough frequencies, underscoring the importance of continuous cough monitoring in pulmonary fibrosis.
